Last updated: February 13, 2026
Overview:
NDC 80644-0012 corresponds to Libtayo (cemiplimab-rwlc), a PD-1 inhibitor developed by Regeneron and Sanofi. It is approved for multiple indications, including cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC). Its market progress reflects strong growth potential driven by expanding indications and competitive landscape.
Market Size and Penetration
Indications and Approved Uses:
- Cutaneous Squamous Cell Carcinoma (CSCC): Approved since 2018
- Basal Cell Carcinoma (BCC): Approved since 2021
- Non-small Cell Lung Cancer (NSCLC): Approved since 2022
- Other indications: In development, such as melanoma and other solid tumors
Market Drivers:
- Rising incidence of skin cancers and lung cancers globally.
- Growing adoption as a first-line therapy in advanced cases.
- Accelerated approval pathways for oncology drugs, shortening time to market.
Market Size (2023 estimates):
- The global oncology immunotherapy market was valued at approximately USD 150 billion.
- Expected CAGR for this segment: 8-10% over the next 5 years.
- For cemiplimab specifically: projected to generate USD 3-5 billion globally by 2026, considering current sales trends and expansion.
Competitive Environment:
| Drug |
Mechanism |
Approved Indications |
Sales (2022) |
Market Share (2022) |
| Cemiplimab (Libtayo) |
PD-1 inhibitor |
Multiple solid tumors |
USD 600 million |
~4-5% of PD-1 inhibitors |
| Pembrolizumab (Keytruda) |
PD-1 inhibitor |
Broad, multiple cancers |
USD 15.5 billion |
~50% of lung + skin indications |
| Nivolumab (Opdivo) |
PD-1 inhibitor |
Multiple, including lung |
USD 8.0 billion |
|
Note: Cemiplimab's market share remains modest but is expanding with new approvals.
Pricing Analysis
Current U.S. Pricing:
- Wholesale Acquisition Cost (WAC): Approximately USD 5,800 - 6,200 per 200 mg dose
- Average treatment course: 2-3 doses for typical indications
- Estimated per-patient cost: USD 12,000 – 20,000
Comparison with Competitors:
| Agent |
Approximate WAC per 200 mg dose |
Typical Course Cost (USD) |
Approved Indications |
| Cemiplimab |
USD 5,800 - 6,200 |
USD 12,000 - 18,600 |
CSCC, BCC, NSCLC |
| Pembrolizumab |
USD 5,800 |
USD 12,000 |
Melanoma, lung, head & neck, others |
| Nivolumab |
USD 5,000 - 6,000 |
USD 10,000 - 18,000 |
Lung, renal, melanoma, others |
Pricing trends: Prices have stabilized but can vary depending on indication, dosing, and payer negotiations.
Propensity for Price Growth or Reduction
- Supply dynamics: Limited competition for same PD-1 class drugs but potential biosimilar or novel competitors could influence price.
- Market expansion: New indications and increasing number of treated patients can sustain or raise revenue.
- Pricing pressures: Cost-containment policies in the U.S. and reimbursement constraints could pressure prices downward.
- Potential discounts: Payer negotiations and outcome-based pricing could reduce net prices by 10-20%.
Pricing projections (2024-2028):
| Year |
Expected Avg. Price per 200 mg dose |
Notes |
| 2024 |
USD 5,700 |
Stable with slight downward pressure |
| 2025 |
USD 5,500 |
Increased competition or negotiated discounts |
| 2026 |
USD 5,300 |
Expansion of indications, but cost pressures persist |
| 2027-2028 |
USD 5,000 - 5,200 |
Increased biosimilar activity, market saturation |
Market Growth and Revenue Forecasts
Key assumptions:
- Steady increase in indications approved.
- Growth in treated patient populations at a CAGR of 12%.
- Continuation of current price levels with slight declines.
Revenue projection for cemiplimab:
| Year |
Estimated Global Sales (USD billion) |
Key Factors |
| 2023 |
USD 0.6 |
Early stage of expansion, limited indications |
| 2024 |
USD 1.0 |
Launch in NSCLC, expanding approvals |
| 2025 |
USD 1.8 |
Additional indications, market penetration |
| 2026 |
USD 2.5 |
Broader use, tighter competition, but expanding market |
Key Takeaways
- The market for cemiplimab (NDC 80644-0012) is expanding driven by new indications and increasing adoption, especially in oncology.
- U.S. prices remain around USD 5,800-6,200 per 200 mg dose, with slight downward adjustments anticipated.
- Overall sales are expected to grow from USD 0.6 billion in 2023 to approximately USD 2.5 billion by 2026.
- Competitive pressures, biosimilar entries, and reimbursement policies will influence pricing strategies.
FAQs
1. What are the primary indications for NDC 80644-0012?
Libtayo is approved for cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
2. How does the current price compare with other PD-1 inhibitors?
Its WAC per 200 mg dose (~USD 5,800-6,200) is comparable to pembrolizumab and nivolumab, but actual patient costs may be lower due to payer negotiations.
3. What factors could influence future price changes?
Introduction of biosimilars, indication expansions, payer negotiations, and policy reforms.
4. What are the main drivers of market growth?
Increasing cancer incidence, approval for new indications, and evolving treatment paradigms.
5. How does competition impact the market for Libtayo?
Dominance is challenged by established PD-1 inhibitors, and biosimilar entries could further depress prices and market share.
References
- IQVIA, 2023. Oncology Market Trends.
- Regeneron Pharmaceuticals, Inc. 2023. Product label for Libtayo.
- GoodRx, 2023. Drug pricing data for PD-1 inhibitors.
- Evaluate Pharma, 2023. Oncology drug forecast report.
- FDA, 2018-2022 approvals.
